Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCB008 in relapsed/refractory AML
NCT05358808Phase 2Terminated
- Sponsor
- TC BioPharm
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TCB008 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by TC BioPharm. Started Aug 2022; status: terminated.
02
Drugs
TCB008
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05358808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358808.